Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.



(f) On December 17, 2021, CinCor Pharma, Inc. (the "Company") filed a
Registration Statement on Form S-1 (File No.: 333-261738) with the Securities
and Exchange Commission, which was subsequently amended (the "Registration
Statement"). Pursuant to Instruction 1 to Item 402(c)(2)(iv) of Regulation S-K,
the Company omitted from the Summary Compensation Table included in the
Registration Statement final annual, performance-based bonus amounts payable to
the Company's named executive officers with respect to performance during the
Company's fiscal year ended December 31, 2021 (the "FY 2021 Annual Incentive
Bonuses") because the FY 2021 Annual Incentive Bonuses had not yet been
determined at the time the Registration Statement was filed.

On January 25, 2022, the Board of Directors of the Company (the "Board"), upon
recommendation by the Compensation Committee (the "Committee") of the Board,
confirmed and approved the FY 2021 Annual Incentive Bonuses for Marc de Garidel,
the Company's Chief Executive Officer, Mary Theresa Coelho, M.B.A., the
Company's Executive Vice President, Chief Financial Officer and Chief Business
Development Officer, and Mason Freeman, M.D., the Company's Executive Vice
President, Clinical Development. In accordance with Item 5.02(f) of Form 8-K,
the Company is providing a revised Summary Compensation Table, which includes
the FY 2021 Annual Incentive Bonuses and revised total compensation figures for
the Company's fiscal year ended December 31, 2021 for each of the foregoing
named executive officers. No other amounts have changed and are qualified in
their entirety by reference to the full text of the Summary Compensation Table
in the section titled "Executive Compensation-Summary Compensation Table" in the
Registration Statement, which is incorporated herein by reference. A narrative
of the Summary Compensation Table is set forth in the section titled "Executive
Compensation-Narrative to the Summary Compensation Table" in the Registration
Statement, which is incorporated herein by reference.

The "Non-Equity Incentive Plan Compensation" column of the following table sets
forth the amounts of the FY 2021 Annual Incentive Bonuses approved by the Board
for each of the named executive officers set forth below:

2021 Summary Compensation Table



The following table sets forth information concerning the compensation of the
Company's named executive officers who were eligible to receive FY 2021 Annual
Incentive Bonuses for the fiscal year ended December 31, 2021.



                                                                                                         Non-Equity
                                                                                       Option          Incentive Plan            All Other
                                                         Salary         Bonus          Awards           Compensation            Compensation
Name and Principal Position                  Year        ($)(1)          ($)             ($)                ($)                     ($)             Total ($)
Marc de Garidel
Chief Executive Officer                       2021        250,000            -         8,807,859              256,507  (2)             30,355        9,344,721
Mary Theresa Coelho, M.B.A.
Executive Vice President, Chief
Financial Officer and Chief Business
Development Officer                           2021         70,385        50,000        2,697,244              147,637  (3)             16,165

2,981,431

Mason Freeman, M.D.
Executive Vice President, Clinical
Development                                   2021         80,000            -         1,783,119               91,562  (4)              2,000        1,956,681

(1) Salary amounts represent actual amounts paid during 2021. See the section

titled "Executive Compensation-Narrative to the Summary Compensation Table"

in the Registration Statement, which is incorporated herein by reference.

(2) Represents (i) Mr. de Garidel's fiscal 2021 performance-based cash bonus

(pro-rated for the portion of fiscal 2021 in which Mr. de Garidel was

employed by the Company) in the amount of $131,507, and (ii) a fiscal 2021


    discretionary bonus for Mr. de Garidel's extraordinary performance in
    connection with the Company's initial public offering in the amount of
    $125,000.

(3) Represents (i) Ms. Coelho's fiscal 2021 performance-based cash bonus

(pro-rated for the portion of fiscal 2021 in which Ms. Coelho was employed by

the Company) in the amount of $35,137, and (ii) a fiscal 2021 discretionary

bonus for Ms. Coelho's extraordinary performance in connection with the

Company's initial public offering in the amount of $112,500.

(4) Represents (i) Dr. Freeman's fiscal 2021 performance-based cash bonus

(pro-rated for the portion of fiscal 2021 in which Dr. Freeman was employed

by the Company) in the amount of $31,562, and (ii) a fiscal 2021

discretionary bonus for Dr. Freeman's extraordinary performance in connection

with the Company's initial public offering in the amount of $60,000.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses